LoPriore Vincent S's Form 4 filing
Hepion Pharmaceuticals, Inc. (HEPA) · filed Aug 12, 2026
- Accession no.
- 0001493152-26-037489
- Filed
- Aug 12, 2026, 9:34 PM ET
- Trade date
- Aug 3, 2026
- Filing delay
- 9 daysLate
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 2 derivative transactions. Open-market purchases total $500.0K. It was filed 9 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| LoPriore Vincent SCIK 0001633927 | Director, Officer (Executive Chairman) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Common Stock | PPurchaseAcquired | +8,000,000 | $0.05 | +$400,000 | 14,250,000 | Indirect | |
| Aug 3, 2026 | Common Stock | PPurchaseAcquired | +2,000,000 | $0.05 | +$100,000 | 16,250,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 3, 2026 | Common Stock | PPurchaseAcquired | +8,000,000 | $0.00 | $0 | 8,000,000 | Indirect | |
| Aug 3, 2026 | Common Stock | PPurchaseAcquired | +2,000,000 | $0.00 | $0 | 10,000,000 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.